Pursuant to Regulation 82(4) of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018 and Regulation 32 (6) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Suven Life Sciences has informed that it enclosed the Monitoring Agency Report regarding utilization of proceeds of the Rights Issue of the Company for the quarter ended on June 30, 2023, issued by CRISIL Ratings.
The above information is a part of company’s filings submitted to BSE.
